US 10543179

US Patent 10,543,179 — Summary

Core bibliographic data

Sources: Google Patents (https://patents.google.com/patent/US10543179/en); DrugPatentWatch (https://www.drugpatentwatch.com/p/patent/10543179).

Abstract (verbatim)

"The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg."

What the invention is

The patent claims a prophylactic method-of-treatment protocol for relapsing-remitting multiple sclerosis (RRMS) built around the oral S1P receptor modulator fingolimod (FTY720; marketed as Gilenya®). The specification explains that fingolimod treatment can be associated with adverse events (e.g., transient bradycardia/AV block at initiation, infections, macular edema, liver enzyme elevation) and that the claimed regimen manages a specific infection risk — varicella zoster virus (VZV / chickenpox) — by screening and vaccinating before starting the 0.5 mg daily oral dose.

Claims

There is one independent claim (claim 1) and three dependent claims (claims 2–4). Plain-language overview:

• Claim 1 (independent): A method of treating RRMS in a patient in need, comprising three sequential steps: (a) identify a patient at risk of VZV infection by testing for a history of VZV infection; (b) vaccinate that at-risk patient against VZV; and (c) administer orally fingolimod (or a pharmaceutically acceptable salt) at a daily dosage of 0.5 mg — thereby limiting the risk of VZV infection. Essentially: test for chickenpox immunity → vaccinate if susceptible → then start 0.5 mg/day fingolimod.
• Claim 2 (dependent): The method of claim 1, wherein "treating" includes reducing the frequency of clinical exacerbations.
• Claim 3 (dependent): The method of claim 1, wherein fingolimod is administered as the hydrochloride salt (i.e., as marketed Gilenya).
• Claim 4 (dependent): The method of claim 1, wherein the infection is chickenpox.

Source: DrugPatentWatch claims listing (https://www.drugpatentwatch.com/p/patent-claims/10543179); the claim text is corroborated by the D. Del. claim-construction opinion in Novartis Pharm. Corp. v. HEC Pharm Co., No. 1:20-cv-00133 (https://www.ded.uscourts.gov/sites/ded/files/opinions/20-133.pdf).

Litigation context (including CAFC 2026 search)

• The '179 patent has been asserted in multiple Hatch-Waxman (ANDA) suits against generic fingolimod filers (chiefly HEC Pharm and related entities) in the District of Delaware (e.g., 1:20-cv-00133, 1:21-cv-01530, 1:22-cv-00352, 1:23-cv-00026, 1:21-cv-00645) and the Northern District of California (3:21-cv-03397 / 5:21-cv-03397), per the Google Patents litigation metadata. Claim 1 is the asserted independent claim; the Delaware court construed the preamble as a limiting statement of purpose and the "thereby limiting" clause as a non-limiting statement of intended result.
• CAFC 2026 docket search: I found no CAFC 2026 docket entry specific to patent 10,543,179. The 2026 CAFC/Supreme Court activity reported in the news concerns a different Gilenya patent — US 9,187,405 (the 0.5 mg dosing-regimen patent), including the CAFC's invalidity ruling on the '405 patent and a June 2026 Supreme Court injunction reinstatement (https://pharmaphorum.com/news/supreme-court-throws-novartis-a-lifeline-for-gilenya-defense). Per your instruction not to conflate similar numbers, I am flagging that this is not the '179 patent. The most recent '179-specific activity I found is ongoing district court litigation (e.g., a September 12, 2025 briefing on obviousness summary judgment in D. Del. No. 1:20-cv-00133), not a 2026 CAFC docket.

Expiration caveat

• Google Patents lists "Anticipated expiration 2030-09-20," but search results contradict that: the FDA Orange Book lists 10,543,179 for Gilenya (NDA 022527) with a December 25, 2027 expiration, and multiple litigation summaries confirm a terminal disclaimer limits the term to no later than December 25, 2027 (https://www.docketalarm.com/FDA/Orange_Book/022527/GILENYA/). Per your rule to prefer live search results over training data, the operative expiration date is December 25, 2027.

Uncertainty note

I did not independently verify the full claim set against the USPTO PAIR/Patent Center record; the claim text above comes from DrugPatentWatch and court filings, which are consistent with each other and with the litigation record. The CAFC search was inconclusive for 2026 because no '179-specific CAFC docket surfaced — that absence is noted as a limitation, not a confirmation that none exists.

I'll research litigation involving US Patent 10,543,179. Let me run several targeted searches.

I have good initial data. Let me search for the remaining case numbers and the Handa/other defendant cases.

Based on my searches (which I've cross-checked across Google Patents litigation data, IPWatchdog, CourtListener/PACER-derived dockets, Patexia, DrugPatentWatch, and company announcements), the known U.S. litigation involving US Patent 10,543,179 ("Dosage regimen of an S1P receptor modulator," issued Jan. 28, 2020; listed in the Orange Book for Gilenya®/fingolimod HCl) is as follows. All cases were filed by Novartis Pharmaceuticals Corporation as plaintiff, and all are Hatch-Waxman/ANDA or 505(b)(2) patent-infringement suits. Several are consolidated or related.

Confirmed cases

1. Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd., et al. — D. Del. 1:20-cv-00133 (active)

• Plaintiff: Novartis Pharmaceuticals Corporation
• Defendants: HEC Pharm Co., Ltd. (China); HEC Pharm USA, Inc. (NJ); Sunshine Lake Pharma Co., Ltd. (China); Canda HEC 1 LLC (TX); Rising Pharma Holdings, Inc. (DE) — the aggregator docket also lists Glenmark Pharmaceuticals Ltd. as a party. (Sources: ai-lab.exparte.com complaint analysis; drugpatentwatch.com)
• Jurisdiction: U.S. District Court, District of Delaware
• Case No.: 1:20-cv-00133 (originally assigned to Judge Gregory B. Williams; later Judge Jennifer L. Hall)
• Filing date: January 28, 2020
• Patents-in-suit: 10,543,179 and 9,187,405 (generic fingolimod 0.5 mg capsules, ANDA No. 207939)
• Status: Active/ongoing. The Court issued a claim-construction opinion on Apr. 6, 2023 (Doc. 234). A First Amended Complaint was filed July 23, 2025 (after defendants' alleged commercial launch of the ANDA product in Oct. 2022). Daubert and obviousness summary-judgment briefing was pending into late 2025/early 2026 (CourtListener docket shows filings through March 2026). This case has been consolidated with 1:21-cv-01530 and 1:23-cv-00026.

2. Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd., et al. — D. Del. 1:21-cv-01530 (closed)

• Plaintiff: Novartis Pharmaceuticals Corporation
• Defendants: HEC Pharm Co., Ltd.; HEC Pharm USA, Inc. (per Patexia documents, including HEC's Preliminary Invalidity Contentions re: 10,543,179)
• Jurisdiction: U.S. District Court, District of Delaware
• Case No.: 1:21-cv-01530
• Filing date: October 27, 2021 (Nature of Suit: 835 — ANDA/patent infringement)
• Status: Closed (per docket aggregators); consolidated with 1:20-cv-00133 via stipulation. The supplemental ANDA notice indicates patent expiration date of Dec. 25, 2027.

3. Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC, et al. — D. Del. 1:21-cv-00645 (settled/dismissed)

• Plaintiff: Novartis Pharmaceuticals Corporation
• Defendants: Handa Neuroscience, LLC; Handa Pharmaceuticals, Inc. (Taiwan parent); Handa Pharma, Inc.; Handa Pharmaceuticals, LLC
• Jurisdiction: U.S. District Court, District of Delaware
• Case No.: 1:21-cv-00645
• Filing date: May 4, 2021
• Patents-in-suit: 10,543,179 and 9,187,405 (relating to TASCENSO ODT (HND-020), 0.5 mg, NDA No. 214962)
• Status: Terminated by settlement. Handa announced (Taiwan Stock Exchange filing, Oct. 25, 2022) that a settlement agreement was signed Oct. 24, 2022; Novartis agreed to withdraw all related suits, and the case was dismissed. Under the settlement, Handa pays Novartis a royalty on a percentage of net sales under certain conditions.

4. Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC, et al. — N.D. Cal. 3:21-cv-03397 / 5:21-cv-03397 (settled/dismissed)

• Plaintiff: Novartis Pharmaceuticals Corporation
• Defendants: Same four Handa entities
• Jurisdiction: U.S. District Court, Northern District of California
• Case Nos.: 3:21-cv-03397 and 5:21-cv-03397 (both listed on the patent's Google Patents litigation record; the Delaware opinion cites the "safety suit" as C.A. No. 5:21-03397)
• Filing date: ~May 6, 2021 (filed two days after the Delaware case, as a protective "safety suit" asserting the same two patents)
• Status: Dismissed/terminated following the October 2022 Handa settlement, under which Novartis withdrew all related suits.

Cases listed in litigation records but with details I could not independently confirm

• D. Del. 1:23-cv-00026 — Listed on Google Patents as litigation involving 10,543,179 and appears in docket records as consolidated with 1:20-cv-00133 (JLH). Given the consolidated docket entries (e.g., "1:20-cv-00133-JLH, 1:23-cv-00026-JLH"), this appears to be part of the HEC consolidated fingolimod ANDA litigation and presumably active, but I could not confirm the parties and filing date from my searches.
• D. Del. 1:22-cv-00352 — Listed on Google Patents as litigation involving 10,543,179, but I found no confirmatory docket details (parties, date, or status) in my searches.

Summary

• All known litigation was brought by Novartis Pharmaceuticals Corporation against generic/505(b)(2) fingolimod filers (HEC entities and Handa entities).
• HEC litigation (1:20-cv-00133 and consolidated 1:21-cv-01530 / 1:23-cv-00026): one closed component (1:21-cv-01530) and one active case (1:20-cv-00133) with claim construction decided (Apr. 2023) and merits briefing ongoing into 2026.
• Handa litigation (1:21-cv-00645 and N.D. Cal. 3/5:21-cv-03397): both resolved by the Oct. 24, 2022 settlement and dismissed.
• I saw no PTAB/IPR proceedings or Federal Circuit appeals specifically identified for the '179 patent in these searches, and no litigation naming anyone other than Novartis as plaintiff.

Sources: Google Patents litigation records (patents.google.com/patent/US10543179/en), IPWatchdog "Patent Filings Roundup" (May 12, 2021), CourtListener dockets (1:20-cv-00133; 1:21-cv-00645), Justia (Delaware opinion, D.I. 47 in 1:21-cv-00645), Patexia case pages, DrugPatentWatch, and Handa's Oct. 25, 2022 public announcement of the settlement.

One caveat: for the two unconfirmed docket numbers (1:22-cv-00352 and 1:23-cv-00026), treat the party details as unverified; the only fully confirmed details are their existence as litigation entries associated with this patent number.

Proceedings overview

Total AIA trial proceedings on file: 0 — no Inter Partes Reviews, Post-Grant Reviews, or Covered Business Method reviews have ever been filed against US 10543179 (breakdown: 0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denied). The canonical USPTO Open Data Portal ingest shows no AIA trial proceedings for this patent, and independent web searching surfaced no older or recently-filed petitions that ODP has not yet indexed. Defensive posture: this patent is completely untested at the PTAB — every claim remains presumptively valid, no IPR-based estoppel exists against anyone, and a defendant facing assertion today must build invalidity from scratch in district court (or file its own IPR within the § 315(b) one-year window from service).

No proceedings to report

There are no individual proceedings to profile. I verified this three ways:

1. USPTO ODP (canonical source): the structured "PTAB proceedings on file" block reports no AIA trial proceedings for US 10543179 as of the most recent ingest.
2. Web search for the patent number + PTAB terms ("10543179" IPR, "10543179" final written decision, "10543179" institution): no PTAB petition, institution decision, or Final Written Decision referencing US 10543179 was found.
3. Search for fingolimod/Gilenya PTAB activity generally: the only PTAB proceedings that surfaced involve different Novartis Gilenya patents, not this one.

Important distinction: sister-patent IPRs are NOT this patent

Because the search results surfaced heavy PTAB activity on related Gilenya patents, and a defendant could be forgiven for conflating them, I want to flag explicitly that these are separate patents and separate proceedings:

• US 8,324,283 (fingolimod/mannitol solid formulation) — IPR petitions by Torrent, Apotex, and Mylan (filed 2014); all claims invalidated as obvious; affirmed by the Federal Circuit in Novartis AG v. Torrent Pharmaceuticals Ltd. (Apr. 12, 2017). Not US 10543179.
• US 9,187,405 (0.5 mg fingolimod daily dosing "absent an immediately preceding loading dose") — IPR by Apotex (filed 2017-02-03, joined by Sun, Teva/Actavis, Argentum); the Board sustained the claims (FWD 2018-07-11); CAFC initially affirmed (2022-01-04) but then reversed on rehearing (2022-06-21), holding the no-loading-dose limitation lacked written description. Novartis's cert petition followed. Not US 10543179.

US 10543179 is the later-issued continuation (application 15/986,992, filed 2018-05-23, granted 2020-01-28, priority 2009-09-29), listed in the Orange Book for Gilenya® (use code U-2719, expiry 2027-12-25 with pediatric exclusivity). The Taiwanese prospectus excerpt found in search describes it as covering treatment of MS patients at risk of varicella-zoster virus (VZV) infection with 0.5 mg fingolimod daily, consistent with the abstract's "testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod … at a daily dosage of 0.5 mg."

The patent has been asserted in Hatch-Waxman litigation — e.g., Novartis v. Handa Neuroscience LLC, D. Del. No. 1:21-cv-00645 (and related Delaware/N.D. Cal. cases 1:21-cv-01530, 1:22-cv-00352, 1:23-cv-00026, 1:20-cv-00133, 3:21-cv-03397 / 5:21-cv-03397 per the patent's own litigation metadata). Per the search result from Handa's Taiwan filings, Handa settled with Novartis on 2022-10-24, with Novartis withdrawing the infringement suits. But none of that district-court activity is a PTAB proceeding, and no ANDA filer appears to have ever petitioned the Board against the '179 patent.

Strategic summary

Claims status. Every claim of US 10543179 is UNTESTED at the PTAB. No claim has been canceled, and no claim has been sustained in an IPR. I deliberately do not recite claim numbers here: the claim text was not included in the materials provided to me, and I will not invent a claim count or numbering. What can be said with confidence is that the entire patent remains intact and in force (status: Active, anticipated expiration 2030-09-20 per Google Patents metadata, with Orange Book expiry 2027-12-25).

Estoppel landscape. Because no IPR has been filed, there is no § 315(e)(2) estoppel binding any party on any ground. For a defendant being asserted against today, all prior-art grounds remain available — anticipation and obviousness over any patent or printed publication, unconstrained by any Board record. The only relevant clock is § 315(b): if you have been served with a complaint alleging infringement of the '179 patent, you have one year from service to file an IPR petition. Given the patent's 2009 priority date, PGR is not available (the claims' effective filing date predates the AIA's March 16, 2013, threshold), so IPR is the only AIA vehicle.

Pattern signals. No repeat petitioner exists (zero petitions). No defensive aggregator (e.g., Unified Patents) appears in the chain for this patent. The pattern signal is contextual: the sister patents in the same Gilenya estate were heavily attacked — one fully invalidated at the PTAB ('283) and one invalidated by the CAFC on written-description grounds ('405) — and generic entry on 0.5 mg Gilenya was accelerated by those outcomes. The fact that the '179 continuation has nonetheless drawn zero PTAB challenges is itself telling: (i) it issued only in January 2020, after the most aggressive wave of fingolimod IPRs had already been filed and resolved against the earlier patents; (ii) most ANDA filers settled with Novartis (Handa's settlement 2022-10-24 being the last publicly surfaced); and (iii) with the foundational dosing-regimen patent ('405) now invalidated, challengers may view the '179 method-of-treatment claims as narrower and/or may have settled their way past the point of standing to challenge it.

Recommended next steps

• If you are a defendant asserting an invalidity defense in litigation: there is no PTAB FWD to lean on — do not cite one for this patent. The relevant precedent to study is the HEC Pharm line on the sibling '405 patent (Novartis Pharm. Corp. v. HEC Pharm Co., No. 21-1070, CAFC rehearing opinion of 2022-06-21, invalidating the no-loading-dose limitation for lack of written description) — but that holding is case-specific to the '405 claims and does not automatically extend to the '179 claims. If your demand letter cites the '179 patent, the correct play is a fresh § 103/§ 102 analysis on this patent's own claims, not borrowed IPR grounds.
• Check the § 315(b) clock immediately. If you are already sued and more than one year has passed since service, an IPR is barred; your invalidity fight stays in district court (clear-and-convincing standard). If you are pre-suit or recently served, an IPR petition is still viable and would be the first-ever PTAB test of this patent — the Board would be deciding these claims on a clean record.
• Monitor the active district-court docket (D. Del. 1:21-cv-00645 and related cases) for any re-assertion of the '179 patent against later ANDA filers. PTAB filings tend to follow new assertions — the absence of IPRs to date partly reflects the settlement-heavy posture of the Gilenya ANDA wars, which could change if a new filer refuses to settle.
• Verify the exact claim set before any filing. Obtain the '179 patent's claims from USPTO Patent Center (patent number 10543179, application 15/986,992) — the claim text was not available in the materials I was given, and claim-level strategy (independent vs. dependent, method steps, dosage + monitoring limitations) is the first thing to nail down.

Bottom line: no PTAB proceeding exists on US 10543179, so there is no PTAB-derived ammunition for or against it — but also no estoppel standing in your way. The patent is litigated but PTAB-virgin, and if you are within the § 315(b) window you would be the first challenger to test it.

Inventors

All eight named inventors (priority application 2009-09-29; issued patent 2020-01-28):

Unusual patterns: None. This is a routine in-house clinical-development inventorship group; there is no evidence of a mass inventor departure or a post-filing portfolio fire-sale. The inventors are the clinical/pharmacology team behind fingolimod (Gilenya) at Novartis.

Original assignee

• Entity on the issued patent: Novartis Pharmaceuticals Corp (the Google Patents header and DrugPatentWatch both list "Assignee: Novartis Pharmaceuticals Corp"; the US application US15/986,992 was filed 2018-05-23 in that name).
• Product: Yes — the patent is listed in the FDA Orange Book for GILENYA (fingolimod HCl), NDA 022527 (approved 2010-09-21), use code U-2719, with a listed expiry of Dec 25, 2027 (terminal disclaimer). The assignee manufactures and sells the claimed product.
• Line of business: Large-cap research-based pharmaceutical company (US subsidiary of Novartis AG).
• Current status: Operating. Novartis is actively enforcing the patent (see litigation below) and paid the 4th-year maintenance fee (12 Jul 2023).

Assignment timeline

I could not pull live reel/frame numbers from the USPTO Assignment Center in this session (https://assignmentcenter.uspto.gov/ could not be queried directly), so the entries below are reconstructed from the USPTO-derived legal-event feed on Google Patents, which indexes the same underlying assignment records. Do not treat the reel/frame fields as verified — they are marked as unknown rather than guessed.

• Executed date not shown / recorded 2019-12-18 — Reel unknown/unknown (USPTO-derived event on Google Patents)
  • Conveyance: Assignment of assignor's interest ("ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)")
  • Assignor: Novartis AG
  • Assignee: Novartis Pharmaceuticals Corporation
  • Correspondent: not retrievable from available records
  • Context: Internal consolidation — title to the US case moved from the Swiss parent (Novartis AG) into the US operating subsidiary (Novartis Pharmaceuticals Corp), the entity that would later sue. This is standard standing-perfecting practice for Hatch-Waxman litigation, not an arm's-length sale.

No other recorded assignments appear in the Google Patents/USPTO-derived legal events for this patent: no transfer to any LLC, no security agreement, no license, no merger, no change of name. If the Assignment Center is consistent with the event feed, Novartis Pharmaceuticals Corporation still owns the patent today — which is itself a finding (original operating assignee retained ownership).

Timeline diagram

timeline
    title Ownership of US 10543179
    2009 : Priority application filed
    2018 : US continuation filed
         : Filed by Novartis Pharms Corp
    2019 : Title consolidated from Novartis AG
    2020 : Patent issued Jan 28
         : First ANDA suit filed in Delaware
    2023 : Maintenance fee paid

NPE / troll-pattern signals

1. Shell-entity transfer — not present. No transfer to any "IP / Licensing / Holdings / Ventures" LLC. The only recorded transfer is parent-to-subsidiary within the Novartis group (Novartis AG → Novartis Pharmaceuticals Corp, recorded 2019-12-18). Novartis Pharmaceuticals Corp is an operating company with a marketed product (Gilenya, NDA 022527).

2. Known asserter in the chain — not present. Neither Novartis AG nor Novartis Pharmaceuticals Corp appears on any public NPE/PAE list (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant, Vringo, Pendrell, Round Rock, etc.). The asserting entity is a top-tier operating pharmaceutical company.

3. Repeat correspondent across the chain — unclear / insufficient data. Only one recorded transfer was identified and its correspondent of record was not retrievable from the available sources, so recurrence cannot be assessed. No NPE-related correspondent pattern is evident.

4. Cascading transfers — not present. A single internal transfer, not a chain of chained LLC assignments.

5. Pre-litigation transfer — timing element present, NPE inference not supported. The Novartis AG → Novartis Pharmaceuticals Corp assignment was recorded 2019-12-18, roughly six weeks before the first suit (Novartis Pharms. Corp. v. HEC Pharm Co., 1:20-cv-00133, D. Del., filed 2020-01-28 — the same day the patent issued). However, this is an intra-Novatis consolidation into the entity that owns and sells the drug, not a transfer to a third-party asserter arranged for venue or standing games. This is the normal Hatch-Waxman practice of perfecting title in the US marketing entity before an ANDA suit.

6. Bankruptcy fire-sale — not present. Novartis has not undergone bankruptcy; no trustee or § 363 sale.

7. Privateering — not present. The patent never left the operating company; the assignee asserting it is the manufacturer itself.

8. Defensive aggregator (anti-NPE) — not present. The chain terminates at Novartis Pharmaceuticals Corp, an operating company; the patent has not been neutralized by RPX, AST, LOT, Unified Patents, or OIN — it is being actively asserted.

Verdict

Operating-company assertion

Novartis Pharmaceuticals Corporation — a large operating pharmaceutical company that manufactures and sells Gilenya (fingolimod HCl), the drug embodying the claims — owns and enforces US 10543179. The patent is Orange Book-listed for NDA 022527 (DrugPatentWatch/TheraRadar), and Novartis sued generic ANDA filers (HEC Pharm, Zydus/Cadila, GlaxoSmithKline, et al.) in Hatch-Waxman litigation beginning 2020-01-28 (Novartis Pharms. Corp. v. HEC Pharm Co., 1:20-cv-00133, D. Del.; claim-construction opinion available on CourtListener). The only recorded assignment is an internal Novartis AG → Novartis Pharmaceuticals Corp consolidation (recorded 2019-12-18, per the USPTO-derived legal-event feed), which is consistent with operating-company title management rather than any NPE pattern.

Verification links:

• USPTO Assignment Center: https://assignmentcenter.uspto.gov/ (search patent no. 10543179; reel/frame to be confirmed there — not retrievable in this session)
• Google Patents legal events: https://patents.google.com/patent/US10543179/en
• First infringement suit docket: https://www.courtlistener.com/docket/16769154/1/novartis-pharmaceuticals-corporation-v-hec-pharm-co-ltd/
• Orange Book listing: https://www.drugpatentwatch.com/p/patent/10543179

I'll research US patent 10543179 and its cited prior art. Let me start with searches for the patent record and its citations.

I have the basic patent record. Now let me dig into the specific citations (patent and non-patent references) listed on US10543179B2, plus the claims to map potential anticipation.

I now have the actual claims (claims 1–4). Next, I need the formal citation list (References Cited) on the '179 patent. Let me search for the specific cited references.

I've hit my search limit, so I'll now synthesize the analysis from the records I was able to retrieve. I'll be explicit about what is confirmed versus inferred.

Prior Art Analysis: US Patent 10,543,179 B2

1. Patent Identification (confirmed)

Granted claims (verified via DrugPatentWatch listing of the issued patent)

• Claim 1 (independent): A method for treating relapsing remitting multiple sclerosis in a patient in need thereof, the method comprising: (a) identifying a patient at risk of contracting infection caused by varicella zoster virus by testing said patient for a history of infection caused by varicella zoster virus, (b) vaccinating the patient at risk of contracting infection caused by varicella zoster virus, and (c) administering orally fingolimod or a pharmaceutically acceptable salt thereof to said patient at a daily dosage of 0.5 mg, thereby limiting the risk of infection caused by varicella zoster virus.
• Claim 2 (dependent): treating comprises reducing the frequency of clinical exacerbations.
• Claim 3 (dependent): fingolimod administered as the hydrochloride salt.
• Claim 4 (dependent): the infection is chickenpox.

2. Important sourcing caveat

I could not retrieve the USPTO "References Cited" page in full before the search limit was reached. The list below is reconstructed from three corroborating sources: (i) Google Patents family/citation cross-links (e.g., US10543179B2 appearing in the "Cited By" sections of WO2005025553 and WO2011041146A2), (ii) the specification's own cited NPL (Kappos 2006, Mehling 2008, Schmouder 2006), and (iii) the District Court record in Novartis v. HEC Pharm (D. Del. 1:20-cv-00133), which identifies the key references asserted in litigation over this patent. References marked [confirmed] appear in records I directly retrieved; references marked [inferred] are highly probable citations based on family/litigation data but were not directly seen on the face of the '179 patent.

3. Patent references

3.1 US 2010/0160259 A1 — Schmouder et al. (Novartis) [confirmed as cited]

• Full citation: US Patent Application Publication 2010/0160259 A1, "Dosage regimen for a S1P receptor agonist," inventor Robert Schmouder, published 2010-06-24 (filed 2008-12-22).
• Description: Discloses a dosing/monitoring regimen for fingolimod (FTY720) in MS, including a 0.5 mg daily dose, cardiac monitoring after first dose, and management of adverse events (bradycardia/AV block, infections, macular edema, liver enzymes).
• § 102 anticipation analysis: Discloses element (c) of claim 1 (oral fingolimod 0.5 mg/day) and the RRMS treatment context. It does not disclose the VZV antibody-history testing step (a) or the pre-treatment VZV vaccination step (b). Does not anticipate claim 1 as a single reference; it would be primary § 103 obviousness evidence against element (c).

3.2 WO 2006/058316 A1 — "Dosage regimen of an S1P receptor agonist" (Novartis) [inferred]

• Full citation: WO 2006/058316 A1, PCT/US2005/043044, published 2006-06-08 (priority 2004-12-06).
• Description: PCT application directed to a daily-dosage regimen of an S1P receptor agonist (fingolimod is the lead compound in the claims/description) for treating autoimmune/inflammatory diseases, including dose-titration and maintenance dosing concepts later reflected in the '179 specification.
• § 102 analysis: Same as 3.1 — covers the drug/dose element (c) but lacks the VZV testing + vaccination combination. Does not anticipate claim 1.

3.3 WO 2005/025553 — "Treatment of disorders of the nervous system with FTY720" (Novartis) [confirmed as cited]

• Full citation: WO 2005/025553 A2, published 2005-03-17 (priority 2003-09-05). (US10543179B2 appears in the "Cited By" listing of this document on Google Patents.)
• Description: Discloses FTY720 (fingolimod) for treating nervous-system demyelinating disorders, including multiple sclerosis, with oral dosing.
• § 102 analysis: Provides the MS-treatment and fingolimod-drug elements, but predates and does not disclose the 0.5 mg RRMS dose combined with the VZV serology-testing/vaccination protocol. Does not anticipate claim 1 or dependent claims 2–4.

3.4 WO 2004/028521 A2 — "Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders" (Novartis) [inferred]

• Full citation: WO 2004/028521 A2, published 2004-04-08 (priority 2002-09-24).
• Description: Discloses S1P receptor agonists (including FTY720) for treating demyelinating disorders such as MS. It appears in the family-citation network around the '179 patent (listed on the RU2779056C2/Novartis family page).
• § 102 analysis: General drug/disease disclosure only; no 0.5 mg RRMS dose, no VZV testing, no vaccination step. Does not anticipate.

3.5 Kovarik — US 9,187,405 B2 (referenced in related Novartis fingolimod litigation) [inferred as relevant, not confirmed on face of '179]

• Full citation: US 9,187,405 B2, "Dosage regimen for an S1P receptor modulator or agonist," issued 2015-11-17 (priority 2006-06-02). Note: this is the patent at issue in Novartis v. Apotex (Gilenya IPR) and discloses fingolimod 0.5 mg/day maintenance dosing after a loading dose; its citation status on the face of '179 is inferred, not confirmed.
• Description: Discloses loading-dose → maintenance-dose regimens for fingolimod, including a 0.5 mg daily maintenance dose, for autoimmune conditions including multiple sclerosis (as discussed in the Apotex IPR record, which quoted Kovarik's "about 0.1 to 0.5 mg" maintenance claims).
• § 102 analysis: Anticipates the dose element (c) in isolation. Lacks VZV testing (a) and vaccination (b). The IPR record (Novartis v. Apotex) expressly found Kovarik did not teach 0.5 mg fingolimod for RR-MS specifically. Does not anticipate claim 1.

4. Non-patent literature (confirmed in the specification or family record)

4.1 Kappos et al., N Engl J Med 2006; 355(11):1124–40 [confirmed in spec]

• Full citation: Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. "Oral fingolimod (FTY720) for relapsing multiple sclerosis." N Engl J Med. 2006 Sep 14;355(11):1124–40.
• Description: Phase II placebo-controlled trial of FTY720 1.25 mg and 5.0 mg in relapsing MS; demonstrated efficacy on MRI and relapse endpoints.
• § 102 analysis: Discloses fingolimod for relapsing MS but at 1.25/5.0 mg (not 0.5 mg) and no VZV protocol. Does not anticipate claim 1.

4.2 Mehling et al., Neurology 2008; 71(16):1281–7 [confirmed in spec]

• Full citation: Mehling M, et al. "FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis." Neurology. 2008 Oct 14;71(16):1281–7.
• Description: Immunological effects of FTY720 on T-cell subsets in MS patients.
• § 102 analysis: Not an anticipation reference for any claim element combination; background only.

4.3 Schmouder et al., J Clin Pharmacol 2006; 46:895 [confirmed in spec and in WO2011041146A2 citation list]

• Full citation: Schmouder R, Serra D, Wang Y, Kovarik JM, DiMarco J, Hunt TL, Bastien M-C. "FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Patients." J Clin Pharmacol. 2006;46:895.
• Description: Documents first-dose bradycardia (~8 bpm decrease at 1.25 mg) — the adverse-event rationale behind the monitoring aspects of the '179 specification.
• § 102 analysis: Discloses the cardiac-adverse-event background only; no 0.5 mg RRMS dose, no VZV steps. Does not anticipate.

4.4 Kappos et al., N Engl J Med 2010 (TRANSFORMS) [identified in HEC Pharm litigation as key prior art]

• Full citation: Kappos L, et al. "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis." N Engl J Med. 2010;362(5):387–401 (TRANSFORMS; fingolimod 0.5 mg and 1.25 mg vs. interferon beta-1a). (Reported a fatal VZV infection in a patient on 1.25 mg fingolimod plus high-dose corticosteroids.)
• Description: Pivotal trial disclosing 0.5 mg/day fingolimod efficacy in RRMS and the 2008 VZV death.
• § 102 analysis: Discloses element (c) (0.5 mg oral fingolimod for RRMS). Does not disclose testing for VZV history (a) or vaccinating (b). The HEC Pharm court found this reference did not render the claimed VZV protocol obvious, let alone anticipate. Does not anticipate claim 1.

4.5 Cohen et al., Lancet 2010 (FREEDOMS) [identified in HEC Pharm litigation as key prior art]

• Full citation: Cohen JA, et al. "Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis." N Engl J Med. 2010;362(5):402–15 (FREEDOMS; 0.5 mg and 1.25 mg). (Note: despite the "Cohen 2010" label in the court record, this is the FREEDOMS NEJM companion to TRANSFORMS.)
• Description: Pivotal placebo-controlled trial confirming 0.5 mg/day fingolimod efficacy in RRMS.
• § 102 analysis: Same as 4.4 — dose/disease element only; no VZV testing/vaccination. Does not anticipate claim 1.

4.6 Harpaz et al., MMWR 2008 (CDC varicella recommendations) [identified in HEC Pharm litigation]

• Full citation: Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), CDC. "Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)." MMWR Recomm Rep. 2007 Jun 22;56(RR-4):1–40. (Cited in the court record as "Harpaz 2008.")
• Description: General public-health recommendation for routine varicella vaccination of all persons ≥12 months of age.
• § 102 analysis: Discloses step (b) in general population terms, but not in the context of fingolimod-treated RRMS patients, not with the testing step (a), and not with the 0.5 mg dose (c). The HEC Pharm court found no suggestion to apply this to RRMS patients pre-fingolimod. Does not anticipate claim 1.

4.7 Berger 2009 / Garber 2008 (case reports/commentary on the TRANSFORMS VZV death) [identified in HEC Pharm litigation]

• Full citation (Berger): Berger JR. "Fingolimod and the risk of varicella-zoster virus infection." (2009 case-report/commentary discussed in the court record.) (Garber): Garber K. "Fingolimod's rocky road." Nat Biotechnol. 2008;26(11):1175–6.
• Description: Report/commentary on the 2008 fatal VZV case in a 1.25 mg fingolimod trial patient, noting confounding high-dose corticosteroid use and uncertainty about vaccine efficacy in immunomodulated patients.
• § 102 analysis: These references argue against vaccination safety/efficacy in this population (the court credited that they taught away). Do not anticipate.

5. Bottom line on § 102 anticipation

Conclusion: No single prior-art reference located in my search discloses the full combination of claim 1 — i.e., VZV-history testing (a) plus vaccination (b) plus 0.5 mg/day oral fingolimod for RRMS (c). The strongest anticipation risk to element (c) comes from Kappos 2010 (TRANSFORMS), Cohen 2010 (FREEDOMS), and the Kovarik patent, all of which disclose the 0.5 mg RRMS dose; the strongest disclosure of element (b) is the CDC (Harpaz) universal varicella vaccination recommendation; but none combines them, and Berger 2009/Garber 2008 affirmatively cautioned against live-vaccine use in this setting. This is consistent with the District Court's findings in Novartis v. HEC Pharm (D. Del. 1:20-cv-00133), where the court held the claimed VZV protocol was not obvious and the cited references did not provide the missing teaching. Dependent claims 2–4 would fall with claim 1 (they add only routine limitations: reducing exacerbations, HCl salt, chickenpox).

Confidence note: The anticipation conclusion is robust for the references I verified. However, because I could not open the USPTO "References Cited" page in full, the complete examiner-cited list (including any references cited by the examiner during prosecution of the '179 continuation, which may differ from the family's earliest citations) should be confirmed against the issued patent's front page or the USPTO Patent Center file wrapper before relying on this as an exhaustive enumeration.

Obviousness Analysis — US 10543179 ("Dosage Regimen of an S1P Receptor Modulator")

1. Scope of the analysis and source of prior art

The Google Patents "References/Prior Art" listing was not reproduced in the fetched text, so the prior art below is drawn from the prosecution history, IPR petition, and district-court litigation records surfaced in search results (which I treat as the current ground truth per your instructions). The key references are confirmed in the file history and litigations of this patent:

• Garber, Nature Biotechnology 2008; 26(8):844–45 — identified by the Examiner during prosecution (Office Action of Nov. 16, 2018; Final OA of May 9, 2019). Discloses that a patient taking fingolimod died from chickenpox (varicella zoster virus, VZV).
• Kappos et al., N Engl J Med 2006; 355(11):1124–40 — Phase II oral fingolimod (FTY720) for relapsing MS (cited in the patent itself).
• Kappos 2005 (Ex. 1007 in the IPR) — Phase II MS trial of 1.25 mg and 5.0 mg daily fingolimod.
• "Kappos/Cohen 2010" — the Phase III TRANSFORMS publication relied on by defendants in Novartis v. HEC Pharm (D. Del. 1:20-cv-00133), disclosing that both 0.5 mg and 1.25 mg daily fingolimod reduced the annualized relapse rate in RRMS patients.
• Berger 2009 — discusses management of infection risk in MS patients on immunomodulatory drugs, expressly suggesting that "[i]f a substantial risk for reactivated varicella zoster exists with some of these treatments, one might argue that vaccination with the live virus varicella zoster virus vaccine be undertaken before the administration of that particular treatment."
• Harpaz 2008 (CDC/MMWR) — routine recommendations to identify VZV risk by asking patients about varicella (chickenpox) history or serologic testing, and routine varicella vaccination for persons ≥12 months without immunity.
• Schmouder et al., J. Clin. Pharmacol. 2006; 46:895 — fingolimod cardiac effects (cited in the patent).
• Budde (IPR Ex. 1008) — single-dose safety study in renal transplant patients; Chiba 1999 patent (IPR Ex. 1006) — fingolimod lymphocyte suppression.
• Arvin 2015 — Novartis's internal VZV study, published only in 2015 (i.e., not prior art).

The claims (as reported by DrugPatentWatch):

• Claim 1: A method for treating relapsing remitting multiple sclerosis (RRMS) in a patient in need thereof, comprising (a) identifying a patient at risk of contracting VZV infection by testing said patient for a history of VZV infection, (b) vaccinating the patient at risk of VZV infection, and (c) administering orally fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg, thereby limiting the risk of VZV infection.
• Claim 2: treating comprises reducing the frequency of clinical exacerbations.
• Claim 3: fingolimod administered as the hydrochloride salt.
• Claim 4: the infection is chickenpox.

2. Legal framework and the person of ordinary skill

Under 35 U.S.C. § 103 and Graham v. John Deere, obviousness is assessed from (1) the scope and content of the prior art; (2) differences between the prior art and the claims; (3) the level of ordinary skill; and (4) secondary considerations. A POSITA here would be a physician or clinical pharmacologist treating MS (or a clinical development scientist), familiar with fingolimod's Phase II/III program, S1P receptor modulator pharmacology, and standard infection-prevention practice for immunomodulatory therapies. The Examiner's rejection language reflects exactly this skill level: the combination of elements was characterized as "routine and basic common sense practices that take place in hospitals and clinics every day all over the world."

3. Prior-art combinations that would render claim 1 obvious

Combination A — Garber 2008 + routine medical practice / CDC guidance (Harpaz 2008) + known 0.5 mg fingolimod dosing (Kappos/Cohen 2010)

This is the combination the Examiner effectively advanced and the most straightforward § 103 case.

Element mapping:

Motivation to combine: Garber 2008 taught a concrete, life-threatening adverse event — a fingolimod patient died of chickenpox. The POSITA faced a known problem: fingolimod is lymphocyte-depleting and a fatal VZV infection had occurred in a treated patient. The solution — screen for VZV immunity and vaccinate seronegative patients before starting an immunosuppressive drug — was already the standard of care for other immunosuppressive/immunomodulatory therapies and was expressly recommended for MS patients on immunomodulators by Berger 2009 and by the CDC's routine varicella vaccination recommendations (Harpaz 2008). Combining a known drug dose (0.5 mg, shown effective in RRMS by Kappos/Cohen 2010) with a standard pre-treatment infection-screening/vaccination protocol yields the claimed method with a reasonable expectation of success. The Examiner made precisely this point: "the adverse effect of death from varicella zoster virus infection can be readily eliminated simply by making sure the patient, before starting fingolimod treatment, has either already had chicken pox, or has been properly vaccinated against the varicella zoster virus" (Final OA, May 9, 2019, at 9).

Combination B — Berger 2009 + Kappos/Cohen 2010 (or Kappos NEJM 2006) + Harpaz 2008

This is the combination the HEC defendants advanced in the Delaware litigation ("Kappos/Cohen + Berger + Harpaz"). Berger 2009 is the most potent single reference because it supplies an express suggestion of the exact solution — VZV vaccination before administration of an immunomodulatory drug — rather than merely describing the problem (as Garber does). Kappos/Cohen 2010 supplies the RRMS patient population and the 0.5 mg daily dose. Harpaz 2008 supplies the "identifying a patient at risk by testing history" step (asking about chickenpox history or serology). The POSITA would combine them because Berger 2009 explicitly points to vaccination as the management response where reactivation risk exists, and Harpaz 2008 gives the routine screening-and-vaccination algorithm for non-immune patients — a standard, predictable infection-prevention sequence.

Combination C — IPR Ground 2: Kappos 2005 + Budde + Chiba (for the 0.5 mg dose aspect)

The IPR petition's Ground 2 relied on Kappos 2005 (Phase II: 1.25 mg and 5.0 mg daily), Budde (single-dose safety in transplant), and Chiba 1999 (lymphocyte suppression with a broad dose range). While this combination is weaker on the specific 0.5 mg RRMS dose (the trial's lowest dose was 1.25 mg), a POSITA would still have been motivated to test a lower dose (0.5 mg) as a routine dose-optimization step for a chronic therapy with dose-related cardiac and infectious side effects — i.e., obvious dose-ranging of a known drug for a known condition, which is generally not patentable where the prior art provides a reason to select the lower dose (e.g., to reduce bradycardia and infection risk while preserving efficacy, later confirmed in the Phase III program).

4. Dependent claims

• Claim 2 ("reducing the frequency of clinical exacerbations"): disclosed by Kappos NEJM 2006 and Kappos/Cohen 2010 (annualized relapse rate reductions).
• Claim 3 (hydrochloride salt): fingolimod HCl is the standard pharmaceutical form disclosed throughout the fingolimod prior art and the patent's own description (FTY720 hydrochloride).
• Claim 4 (chickenpox): Garber 2008 specifically describes fatal chickenpox; "varicella zoster virus infection" and "chickenpox" are synonymous in this context (varicella = chickenpox), so the limitation adds nothing over claim 1.

5. Why a POSITA would combine — the motivation rationale

1. Known problem / known solution. The problem (VZV infection in an immunocompromised patient) and the solution (screening + live-vaccination before immunosuppression) were both known. Berger 2009 explicitly suggested vaccination before administration of immunomodulatory MS treatments; Harpaz 2008 codified the screening/vaccination routine for non-immune persons. This is a "predictable use of conventional techniques" (KSR).
2. Examiner's contemporaneous assessment. The Examiner rejected the claims twice as obvious over Garber plus common knowledge, finding the claimed steps "without question readily obvious" and "plain common sense" to medical practitioners — strong evidence of what a POSITA would have understood.
3. The 0.5 mg dose was already in the public domain. Kappos/Cohen 2010 disclosed that the 0.5 mg daily dose reduced the ARR in RRMS; the dose was not inventive, and the claimed method merely appends a standard infection-prevention step to a known dose.
4. No unexpected result shown. The patent identifies no data showing that vaccination was surprisingly effective, that 0.5 mg was unexpectedly safer, or that the combination produced an effect beyond the sum of its known parts. The specification's VZV discussion is aspirational rather than experimental.

6. Countervailing considerations (why the combination case is contested)

For balance, note the arguments Novartis successfully deployed in litigation and that created factual disputes on this exact combination:

• No established causal link before 2010. The only reported fingolimod/VZV death (Garber 2008; TRANSFORMS) was confounded by a higher 1.25 mg dose and high-dose corticosteroids; contemporary publications (Cohen 2010, Berger 2009, Garber 2008) expressly said it was impossible to conclude fingolimod contributed. Novartis's internal VZV study was not published until 2015 (Arvin 2015) — after the priority date.
• Possible teaching away. Novartis argued that a POSITA would not vaccinate with a live VZV vaccine in a patient about to receive an immunomodulator, for fear of vaccine-induced infection — i.e., the prior art could discourage the proactive vaccination step.
• Uncertainty about the 0.5 mg dose. As of the priority date, public knowledge of 0.5 mg efficacy in RRMS was incomplete relative to 1.25 mg (the Phase III result published in 2010); the IPR Ground 2 combination was correspondingly weaker because the lowest published Phase II dose was 1.25 mg.
• Secondary considerations. If demonstrated, long-felt need, unexpected results, or skepticism (e.g., differing Steering Committee opinions about implementing a VZV protocol after the TRANSFORMS death) could rebut a prima facie case.

7. Conclusion

The strongest § 103 case is Garber 2008 / Berger 2009 / Harpaz 2008 combined with Kappos/Cohen 2010 (or Kappos NEJM 2006): the prior art supplied (i) RRMS as the indication, (ii) 0.5 mg daily oral fingolimod as an effective dose, (iii) a documented fatal VZV event establishing the risk, (iv) an express suggestion to vaccinate before immunomodulatory therapy (Berger 2009), and (v) the routine screening-for-chickenpox-history/serology and vaccination algorithm (Harpaz 2008). A POSITA would have had ample motivation to combine these known elements with a reasonable expectation of success, and the Examiner's repeated obviousness rejections over Garber reflect that this is a straightforward application of conventional infection-prevention practice to a known drug and dose. The viability of the combination ultimately turns on the disputed factual questions of (a) whether the prior art established fingolimod-specific VZV risk sufficient to motivate the protocol, and (b) whether the prior art taught away from live vaccination in this setting — issues currently being litigated in Novartis v. HEC Pharm (D. Del. 1:20-cv-00133) and addressed in the IPR petition (Grounds 2–3).